Welcome

Photo of STA Office

Specialised Therapeutics Australia (STA) is dedicated to working with leading biotechnology and pharmaceutical companies worldwide to make specialised therapies available to people living in Australia and New Zealand.

STA is an independent and privately owned company based in Melbourne, Australia. Carlo Montagner and Bozena Zembrzuski, who are both highly experienced globally in pharmaceutical commercialisation, founded STA in 2007.

At STA, our primary objective is to enable people living in Australia and New Zealand with high unmet medical needs, unrestricted access to breakthrough acute care therapies.

The STA therapeutic portfolio and pipeline currently encompasses oncology and infectious diseases. STA also has interests in other therapies such as haematology, respiratory, dermatology, endocrinology and central nervous system disorders.

STA has launched in Australia and New Zealand two leading therapies in the field of oncology: ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer and ALOXI® (palonosetron HCl) for the amelioration of nausea and vomiting associated with many cancer therapies. Other treatments available include DIFICID® and GLIOLAN®

March, 2014: Rare Cancers Australia - A focus on less common cancers

Two articles / reports on less common cancers from Rare Cancers Australia.

Read More

Jan, 2014: Updated Pancreatic Cancer Data Presented At International Cancer Conference

A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.

Read More

Jun, 2013: Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.

Read More

Nov, 2012: ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.

Read More

Oct, 2012: ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study

Specialised Therapeutics Australia (STA) is pleased to announce the results of the phase III, randomised, international study (CA033) of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in chemotherapy-naïve patients with metastatic melanoma.

Read More

Oct 2014: STA Announces Breakthrough Cancer Drug ABRAXANE® to be PBS Listed for Metastatic Pancreatic Cancer

ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer from the 1st of November.

Read More

Apr 2014: STA to License New Drug – Iluvien® – to Improve Vision in Patients with Diabetes-Induced Vision Loss

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM).

Read More

Mar 2014: STA Receives TGA Approval for Abraxane® in Combination with Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer

Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer.

Read More

Jan 2014: ARIAD Announces Commercial Agreement for Iclusig® (ponatinib) in Australia

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias.

Read More

Jan 2014: Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients

Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc.

Read More